InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.07
(
-0.07%
)
Bitcoin
64,043.49
(
0.07%
)
Post# of 124
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

keekee

Send PM Follow Ignore
Followers 108
Posts 3850
Boards Moderated 0
Alias Born 09/29/2011

keekee

Re: ValueInvestor15 post# 70

Friday, 09/30/2016 8:42:30 AM

Friday, September 30, 2016 8:42:30 AM

Post# of 124
Cantor Fitzgerald maintained its "buy" rating and $16 price target on the stock today following the announcement.

"We have liked the reworked phase III MEASURE study, which has been a key component of our investment thesis," the firm said.

Any issues the FDA has with preclinical information "could be resolved," Cantor added.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up